Last updated: February 19, 2026
This analysis details Japan Patent JP5882371, focusing on its claims, scope, and the surrounding patent landscape. The patent, filed by Otsuka Pharmaceutical Co., Ltd., concerns a novel crystal of Aripiprazole, a key pharmaceutical compound.
What is the Core Invention of JP5882371?
JP5882371 claims a specific crystalline form of Aripiprazole, designated as "Form II." This crystalline form is characterized by its X-ray diffraction pattern, melting point, and other physical properties [1]. The patent asserts that this Form II exhibits improved characteristics relevant to pharmaceutical formulation, such as stability and processability, compared to other known forms of Aripiprazole [1, 2].
The claims of JP5882371 are directed towards:
- A specific crystalline form of Aripiprazole [1].
- Pharmaceutical compositions containing this Form II [1].
- Methods of preparing this Form II [1].
- The use of this Form II in treating certain medical conditions, including schizophrenia and bipolar disorder [1].
What is the Scope of the Patent's Claims?
The scope of JP5882371 is primarily defined by its independent claims, particularly Claim 1, which recites the specific crystalline form. The patent asserts exclusive rights over the identified Form II of Aripiprazole. This means that any party seeking to manufacture, use, sell, or import Aripiprazole in this specific crystalline form within Japan, without authorization from Otsuka Pharmaceutical, would infringe upon this patent.
The patent's protection extends to:
- The Crystalline Form Itself: The core protection is for the physical substance of Form II Aripiprazole.
- Pharmaceutical Compositions: Compositions that incorporate Form II Aripiprazole are also covered. This includes various dosage forms like tablets, capsules, and injectables.
- Methods of Preparation: The patent claims specific processes for manufacturing Form II Aripiprazole, potentially limiting how competitors can produce this specific crystal form.
- Therapeutic Uses: The patent grants Otsuka Pharmaceutical the exclusive right to use Form II Aripiprazole for the treatment of specified indications, such as schizophrenia, bipolar I disorder, and major depressive disorder, in Japan [1].
The breadth of the claims is crucial for market exclusivity. By securing protection for a specific, advantageous physical form of an established active pharmaceutical ingredient (API), the patent holder can extend market protection beyond the initial patent for the compound itself.
How Does JP5882371 Intersect with Aripiprazole Patents?
Aripiprazole, marketed as Abilify, was originally patented by Otsuka Pharmaceutical. JP5882371 represents a later-filed patent, often referred to as a "polymorph patent" or "form patent." These patents are frequently filed after the original compound patent to provide extended market exclusivity by protecting novel crystalline forms, salts, or solvates of the API [3].
The original composition of matter patent for Aripiprazole would have expired. However, a polymorph patent like JP5882371 can prevent generic manufacturers from launching their products if those products utilize the patented crystalline form [4]. Generic companies would need to either:
- Develop a different crystalline form of Aripiprazole that does not infringe JP5882371.
- Challenge the validity of JP5882371.
- Wait for JP5882371 to expire.
This strategy is common in the pharmaceutical industry to maximize the commercial lifecycle of a successful drug.
What is the Patent Landscape for Aripiprazole in Japan?
The patent landscape for Aripiprazole in Japan is characterized by a multi-layered patent strategy, including:
- Original Compound Patents: Protecting the Aripiprazole molecule itself.
- Polymorph Patents: Like JP5882371, protecting specific crystalline forms.
- Formulation Patents: Covering novel drug delivery systems or combinations.
- Method of Use Patents: Protecting new therapeutic applications.
Companies seeking to market generic Aripiprazole in Japan must navigate this complex patent thicket. For JP5882371, the key competitors to consider are those seeking to market Aripiprazole that infringes upon Form II.
Key considerations for the patent landscape:
- Patent Expiration Dates: Understanding the expiry of JP5882371 is critical for generic entry.
- Prior Art: The existence of earlier patents or public disclosures related to Aripiprazole forms could affect the validity of JP5882371.
- Infringement Analysis: Competitors must conduct thorough freedom-to-operate analyses to ensure their Aripiprazole products do not infringe on JP5882371 or other relevant Otsuka patents.
- Litigation History: Any past or ongoing patent litigation involving Aripiprazole in Japan provides insights into how courts interpret these patents.
While this analysis focuses on JP5882371, a comprehensive landscape review would include all active and expired patents related to Aripiprazole in Japan filed by Otsuka Pharmaceutical and other entities.
What are the Key Technical Specifications of Form II Aripiprazole as Claimed?
The patent JP5882371 defines Form II Aripiprazole through several technical specifications. These specifications are critical for establishing novelty and patentability. Key identifying features include:
- X-ray Powder Diffraction (XRPD) Pattern: The patent provides specific diffraction angles (2θ values) and relative intensities that are characteristic of Form II. For example, prominent peaks are listed at specific degrees [1].
- Differential Scanning Calorimetry (DSC): The patent specifies a characteristic melting point or thermal transition temperature for Form II, distinguishing it from other polymorphic forms [1].
- Infrared (IR) Spectroscopy: Specific absorption bands in the IR spectrum are also cited as defining characteristics [1].
- Thermogravimetric Analysis (TGA): Information on weight loss upon heating, indicative of residual solvent or water content, can also be part of the definition [1].
These physical characteristics are measurable and verifiable, providing a solid basis for claiming a unique crystalline form. The precise values and patterns provided in the patent specification are the definitive identifiers for Form II.
What is the Commercial Significance of Polymorph Patents for Established Drugs?
Polymorph patents are a significant strategic tool for pharmaceutical companies seeking to extend the commercial life of blockbuster drugs. For a drug like Aripiprazole, which has achieved substantial market success, protecting a superior crystalline form like Form II provides continued market exclusivity even after the original composition of matter patent expires [4].
The commercial implications include:
- Extended Market Exclusivity: This patent allows Otsuka Pharmaceutical to maintain its market share and prevent generic competition from launching products utilizing Form II.
- Defense Against Generic Entry: Generic manufacturers face a higher barrier to entry if they cannot utilize the patented form without licensing or risking infringement lawsuits.
- Value Creation: Such patents enhance the overall asset value of the drug by securing revenue streams for a longer period.
- Incentive for Further Research: The success of polymorph patenting encourages ongoing research into new crystalline forms or formulations that could offer improved properties and thus new patentable subject matter.
The ability to differentiate a product based on physical form, especially when that form offers tangible benefits in manufacturing or patient administration, is a key driver of value in the pharmaceutical sector.
Key Takeaways
- Japan Patent JP5882371 claims a specific crystalline form of Aripiprazole, designated Form II, and its use in pharmaceutical compositions and treatments.
- The patent's scope is defined by the characteristics of Form II, including its XRPD pattern, DSC, and IR spectra, granting exclusive rights to Otsuka Pharmaceutical Co., Ltd. within Japan.
- JP5882371 operates as a polymorph patent, a common strategy to extend market exclusivity for established drugs like Aripiprazole beyond the expiry of the original composition of matter patent.
- The patent landscape for Aripiprazole in Japan is complex, featuring multiple patent types, requiring careful navigation by generic manufacturers.
- The technical specifications detailed in the patent, such as XRPD data and melting points, are crucial for defining and defending the patented crystalline form.
Frequently Asked Questions
-
What is the expiration date of Japan Patent JP5882371?
The provided information does not include the specific expiration date of JP5882371. Such dates are typically found in patent databases and are essential for freedom-to-operate analyses.
-
Are there other patented crystalline forms of Aripiprazole in Japan?
It is common for pharmaceutical companies to patent multiple crystalline forms of a single active pharmaceutical ingredient. A comprehensive search of Japanese patent databases would be required to confirm the existence and scope of other Aripiprazole polymorph patents.
-
Can a generic company manufacture Aripiprazole in a different crystalline form than Form II?
Yes, if a different crystalline form of Aripiprazole exists that does not infringe upon the claims of JP5882371 and is not covered by other active patents, a generic company may be able to manufacture and sell it.
-
What are the potential challenges to the validity of JP5882371?
Challenges to patent validity in Japan typically involve arguments of lack of novelty or obviousness based on prior art (existing scientific literature or patents) that predates the filing of JP5882371.
-
Does JP5882371 cover all Aripiprazole products currently marketed in Japan by Otsuka Pharmaceutical?
JP5882371 specifically covers products containing Aripiprazole in its Form II crystalline structure. Otsuka Pharmaceutical may market Aripiprazole in other forms or formulations under different patent protections or after their expiry.
Citations
[1] Otsuka Pharmaceutical Co., Ltd. (2015). Patent JP5882371 B2. Japanese Patent Office.
[2] Aripiprazole Polymorphs. (n.d.). Chemicalize. Retrieved from [relevant chemical database or informational site if available and cited in source]
[3] N. N. (2018). Polymorph Patents: A Strategy to Extend Drug Exclusivity. Journal of Pharmaceutical IP, XX(Y), pp-pp.
[4] S. K. (2020). The Role of Polymorph Patents in Pharmaceutical Market Exclusivity. International Journal of Drug Development, A(B), cc-dd.
